2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.22

PP02.22 - Yoo-kang Kwak

Pdf Summary

The study investigates the efficacy of durvalumab as a consolidation therapy following concurrent chemoradiotherapy in patients with inoperable stage III non-small cell lung cancer (NSCLC). Based on findings from the PACIFIC trial, durvalumab is established as a standard care to improve progression-free survival (PFS) and overall survival (OS). The research focuses on real-world data to assess outcomes and identify prognostic factors.<br /><br />A retrospective review was conducted on 107 patients who received concurrent platinum-based chemotherapy and radiotherapy with doses between 50 Gy and 72.6 Gy. Primary endpoints analyzed were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier survival analysis and Cox proportional hazard regression models were utilized to identify significant prognostic factors.<br /><br />Key results include a median follow-up period of 16.5 months, with median OS of 32.3 months and median PFS of 18.7 months. Durvalumab's impact on survival was non-statistically significant; however, further follow-up may provide stronger evidence of benefits. For durvalumab-treated patients, the 2-year OS was 64.1% compared to 48.0% for those not receiving durvalumab, and 2-year PFS was 46.1% versus 40.1%. <br /><br />Prognostic factors affecting OS included histology and T stage, while those affecting PFS involved smoking status and response to chemoradiotherapy (CCRT). The study implies that durvalumab may enhance survival outcomes following CCRT in stage III NSCLC patients, but longer follow-up and additional data are necessary for robust conclusions. It suggests the need for continued evaluation of diverse clinical factors in treating NSCLC.

Keywords

durvalumab

consolidation therapy

non-small cell lung cancer

NSCLC

PACIFIC trial

progression-free survival

overall survival

prognostic factors

chemoradiotherapy

real-world data